Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

Adverse events; Cetuximab; Encorafenib

Detalles Bibliográficos
Autores: Tabernero Caturla, Josep, Velez, L, Trevino, T. L., Grothey, Axel, Van Cutsem, Eric, Yaeger, Rona
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:España
Institución:Departament de Salut de la Generalitat de Catalunya (DS)
Repositorio:Scientia. Dipòsit d'Informació Digital del Departament de Salut
OAI Identifier:oai:scientiasalut.gencat.cat:11351/7739
Acceso en línea:https://hdl.handle.net/11351/7739
Access Level:acceso abierto
Palabra clave:Medicaments - Efectes secundaris
Còlon - Càncer - Tractament
Recte - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
id ES_d286c5e708a9f610fd71c8de96864a2b
oai_identifier_str oai:scientiasalut.gencat.cat:11351/7739
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
title Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
spellingShingle Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
Tabernero Caturla, Josep
Medicaments - Efectes secundaris
Còlon - Càncer - Tractament
Recte - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
title_short Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
title_full Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
title_fullStr Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
title_full_unstemmed Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
title_sort Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
dc.creator.none.fl_str_mv Tabernero Caturla, Josep
Velez, L
Trevino, T. L.
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
author Tabernero Caturla, Josep
author_facet Tabernero Caturla, Josep
Velez, L
Trevino, T. L.
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
author_role author
author2 Velez, L
Trevino, T. L.
Grothey, Axel
Van Cutsem, Eric
Yaeger, Rona
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Tabernero J, Velez L] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVIC-UCC, IOB-Quiron, Barcelona, Spain. [Trevino TL] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. [Grothey A] West Cancer Center and Research Institute, OneOncology, Germantown, USA. [Yaeger R] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA. [Van Cutsem E] Digestive Oncology Department, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Medicaments - Efectes secundaris
Còlon - Càncer - Tractament
Recte - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
topic Medicaments - Efectes secundaris
Còlon - Càncer - Tractament
Recte - Càncer - Tractament
DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms
Other subheadings::Other subheadings::Other subheadings::/drug therapy
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
Other subheadings::Other subheadings::Other subheadings::/adverse effects
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
description Adverse events; Cetuximab; Encorafenib
publishDate 2021
dc.date.none.fl_str_mv 2021
2022
2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/7739
url https://hdl.handle.net/11351/7739
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv ESMO Open;6(6)
https://doi.org/10.1016/j.esmoop.2021.100328
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Scientia
reponame:Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname:Departament de Salut de la Generalitat de Catalunya (DS)
instname_str Departament de Salut de la Generalitat de Catalunya (DS)
reponame_str Scientia. Dipòsit d'Informació Digital del Departament de Salut
collection Scientia. Dipòsit d'Informació Digital del Departament de Salut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420380820602880
spelling Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC studyTabernero Caturla, JosepVelez, LTrevino, T. L.Grothey, AxelVan Cutsem, EricYaeger, RonaMedicaments - Efectes secundarisCòlon - Càncer - TractamentRecte - Càncer - TractamentDISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal NeoplasmsOther subheadings::Other subheadings::Other subheadings::/drug therapyANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy ProtocolsOther subheadings::Other subheadings::Other subheadings::/adverse effectsENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectalesOtros calificadores::Otros calificadores::Otros calificadores::/farmacoterapiaTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinadaOtros calificadores::Otros calificadores::Otros calificadores::/efectos adversosAdverse events; Cetuximab; EncorafenibEventos adversos; Cetuximab; EncorafenibEsdeveniments adversos; Cetuximab; EncorafenibColorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor inhibitor cetuximab currently represents the only chemotherapy-free targeted therapy approved in the USA and Europe for previously treated patients with BRAF V600E-mutated mCRC. As a class, BRAF inhibitors are associated with dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies. Adverse event (AE) profiles of specific BRAF inhibitors vary, however, and are affected by the specific agents given in combination. In patients with mCRC, commonly reported AEs of cetuximab monotherapy include infusion reactions and dermatologic toxicities. Data from the phase III BEACON CRC study indicate that the combination of encorafenib with cetuximab has a distinct safety profile. Here we review the most frequently reported AEs that occurred with this combination in BEACON CRC and best practices for managing and mitigating AEs that require more than standard supportive care.This work was supported by Array BioPharma in collaboration with Merck KGaA Darmstadt, Germany (for sites outside of North America), ONO Pharmaceutical, Japan, and Pierre Fabre, France. Array BioPharma was acquired by Pfizer in July 2019. This work was also supported by the Cancer Center Core [grant number P30 CA 008748] to MSKCC. Medical writing/editorial support was provided by Namiko Abe, PhD, and Alyson Bexfield, PhD, of Caudex, New York, and was funded by Pfizer.ElsevierInstitut Català de la Salut[Tabernero J, Velez L] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVIC-UCC, IOB-Quiron, Barcelona, Spain. [Trevino TL] Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA. [Grothey A] West Cancer Center and Research Institute, OneOncology, Germantown, USA. [Yaeger R] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA. [Van Cutsem E] Digestive Oncology Department, University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, BelgiumVall d'Hebron Barcelona Hospital Campus202220222021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/7739Scientiareponame:Scientia. Dipòsit d'Informació Digital del Departament de Salutinstname:Departament de Salut de la Generalitat de Catalunya (DS)InglésESMO Open;6(6)https://doi.org/10.1016/j.esmoop.2021.100328Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:scientiasalut.gencat.cat:11351/77392026-06-12T09:38:37Z
score 15,228081

Similares en LA Referencia